Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
AJR Am J Roentgenol ; 219(5): 752-761, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-35642761

RESUMO

BACKGROUND. Additional evidence of the role of COVID-19 vaccination in reducing pneumonia frequency and severity in the setting of breakthrough infection could help combat ongoing vaccine hesitancy. OBJECTIVE. The purpose of this article was to compare the frequency and severity of pneumonia on chest CT in patients with confirmed COVID-19 between patients who are unvaccinated and those who are fully vaccinated by messenger RNA (mRNA) or adenovirus vector vaccines. METHODS. This retrospective single-center study included 467 patients (250 men, 217 women; mean age, 65 ± 17 [SD] years) who underwent chest CT between December 15, 2021, and February 18, 2022, during hospitalization for symptomatic COVID-19, confirmed by reverse transcriptase-polymerase chain reaction assay. A total of 216 patients were unvaccinated, and 167 and 84 patients were fully vaccinated (defined as receipt of the second dose at least 14 days before COVID-19 diagnosis) by the BNT162b2 mRNA vaccine or the ChAdOx1-S adenovirus vector vaccine, respectively. Semiquantitative CT severity scores (CT-SS; 0-25 scale) were determined; CT-SS of 0 indicated absence of pneumonia. Presence of bilateral involvement was assessed in patients with pneumonia. Associations were explored between vaccination status and CT findings. RESULTS. The frequency of the absence of pneumonia was 15% (32/216) in unvaccinated patients, 29% (24/84) in patients fully vaccinated with ChAdOx1-S vaccine, and 51% (85/167) in patients fully vaccinated with BNT162b2 vaccine (unvaccinated and ChAdOx1-S vs BNT162b2: p < .001; unvaccinated vs ChAdOx1-S: p = .08). Mean CT-SS was significantly higher in unvaccinated patients (9.7 ± 6.1) than in patients fully vaccinated with BNT162b2 (5.2 ± 6.1) or ChAdOx1-S (6.2 ± 5.9) vaccine (both p < .001). Full vaccination was significantly associated with CT-SS independent of patient age and sex (estimate = -4.46; p < .001). Frequency of bilateral lung involvement was significantly higher in unvaccinated patients (158/184, 86%) and in patients fully vaccinated with ChAdOx1-S vaccine (54/60, 90%) than in patients fully vaccinated with BNT162b2 vaccine (47/82, 57%) (both p < .001). CONCLUSION. Pneumonia frequency and severity were lower in patients with full vaccination by mRNA and adenovirus vector vaccines who experienced breakthrough infections in comparison with unvaccinated patients. CLINICAL IMPACT. The visual observation by radiologic imaging of the protective effect of vaccination on lung injury in patients with breakthrough infections provides additional evidence supporting the clinical benefit of vaccination.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adenoviridae/genética , Vacina BNT162 , COVID-19/fisiopatologia , COVID-19/prevenção & controle , Teste para COVID-19 , Vacinas contra COVID-19/uso terapêutico , Estudos Retrospectivos , DNA Polimerase Dirigida por RNA , ChAdOx1 nCoV-19
4.
ACG Case Rep J ; 9(1): e00744, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-35018294

RESUMO

Endoscopic sphincterotomy (ES) is commonly performed during endoscopic retrograde cholangiopancreatography, and bleeding is a severe adverse event. PuraStat is a peptide developed as a hemostatic agent for endoscopy. We report its use as a hemostatic strategy in post-ES bleeding refractory to combined hemostasis. A patient with choledocholithiasis underwent endoscopic retrograde cholangiopancreatography for stone removal. After the ES, severe bleeding refractory to the injection of diluted epinephrine around the bleeding source and metal stent placement occurred. Hemostasis was achieved with the application of the hemostatic gel. We reported the use of novel self-assembling hemostatic gel as an effective therapeutic tool for post-ES refractory bleeding.

5.
J Neurol ; 250(10): 1206-8, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14586603

RESUMO

Sixty patients admitted to hospital for hemispherical ischemic stroke causing severe disabilities were enrolled in the study. The patients were divided in two groups: A and B. The patients in group A were given intensive rehabilitative treatment; those in group B were given ordinary rehabilitative treatment. Both treatments lasted 14 days. At the end of that period, the patients of both groups were sent to the same rehabilitation center to continue treatment, using the same methods for all. The patients were evaluated by means of the modified N. I. H. Stroke Scale and the Barthel-Index on the day of enrollment, on the 14(th) and 180(th) day. The results obtained from intensive treatment were no better than those obtained from ordinary treatment. This study shows that there is no point in adopting an intensive rehabilitative treatment for an ischemic stroke in its acute phase: a more expensive and time-consuming effort does not in any way lead to a better outcome.


Assuntos
Isquemia Encefálica/reabilitação , Reabilitação/métodos , Reabilitação do Acidente Vascular Cerebral , Doença Aguda , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA